Koselugo - the first FDA-approved treatment shown to reduce the size of plexiform neurofibromas (PN) - has made lifechanging impacts on NF1-patients and caregivers. New improvements could result in no longer needing to fast to accommodate treatment.

Explore the groundbreaking Phase 2b ReNeu trial by SpringWorks Therapeutics, showcasing the potential of mirdametinib in transforming the treatment landscape for Neurofibromatosis Type 1.

SketchNF is dedicated to raising funds and creating a network for pediatric NF patients one sketch at a time. Their mission is to empower children with NF by allowing them to share their stories and hopes through the form of art. Join us for the 2nd annual auction this May!

Timothy Gross, who has been running for the last seven years despite his hearing loss due to neurofibromatosis, will lead a charity race to raise awareness for NF this month.